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INTRODUCTION 
Diabetes mellitus (DM), characterized by metabolic disorders related to high 
levels of serum glucose, is probably the most associated disease to Mg depletion 
in intra and extra cellular compartments5. Hypomagnesemia has been related as 
a cause of insulin resistance, also being a consequence of hyperglycemia, and 
when it is chronic leads to the installation of macro and microvascular 
complications of diabetes, worsening the deficiency of Mg. The mechanism 
involving the DM and hypomagnesemia was still unclear, although some 
metabolic studies demonstrate that Mg supplementation has a beneficial effect in 
the action of insulin and in the glucose metabolism. 
Hypomagnesemia has long been known to be associated with diabetes 
mellitus. Low serum magnesium level has been reported in children with insulin 
dependent diabetes mellitus and through the entire spectrum of adult type1 and 
type 2 diabetes mellitus regardless of the type of therapy. 
Initially the cause of hypomagnesaemia was attributed to osmotic renal losses 
from glycosuria decreased intestinal magnesium absorption and redistribution of 
magnesium from plasma into red blood cells caused by insulin effect. Recently a 
specific tubular magnesium defect in diabetes has been postulated. 
Hypermagnesuria results specifically from a reduction in tubular absorption of 
magnesium. 
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Magnesium is involved on multiple levels in insulin secretion, binding and 
activity. Cellular magnesium deficiency can alter of the membrane bound 
sodium-potassium-adenosine triphospatase which is involved in the maintenance 
of gradients of sodium and potassium and in glucose transport. 
The concentrations of magnesium in serum of healthy people are 
remarkably constant, whereas 25-39% of diabetics have low concentrations of 
serum magnesium6,7.
 
Magnesium depletion has a negative impact on glucose 
homeostasis and insulin sensitivity in patients with type 2 diabetes8,9,
 
as well as 
on the evolution of complications such as retinopathy10, arterial atherosclerosis 
and nephropathy.
 
Moreover, low serum magnesium is a strong, independent 
predictor of development of type 2 diabetes. 
The present study was undertaken with an aim to estimate prevalence of 
hypomagnesaemia in patients with type 2 DM and to correlate the serum 
magnesium concentrations with micro and macrovascular complications of 
diabetes – retinopathy, nephropathy, neuropathy and ischemic heart disease. 
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AIM OF THE STUDY 
This study is aimed at,  
1. Estimating fasting serum magnesium concentrations in patients with 
 type 2 diabetes mellitus.  
2. Correlating serum magnesium concentrations with micro and 
macrovascular complications of type 2 diabetes mellitus - retinopathy, 
nephropathy, neuropathy and ischemic heart disease.  
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DIABETES MELLITUS 
 Diabetes is a chronic illness that requires continuing medical care and 
ongoing patient self-management education and support to prevent acute 
complications and to reduce the risk of long-term complications. Diabetes care 
is complex and requires that many issues, beyond glycemic control, be 
addressed.
1
 A large body of evidence exists that supports a range of 
interventions to improve diabetes outcomes. 
Major advances in the understanding of diabetes and metabolism have 
included:  
A. The sequencing of insulin in 1955 by Frederick Sanger and elucidation of 
its three dimensional structure in 1969 by Dorothy Hodgkin.  
B. The measurement of insulin concentration using the first radio 
immunoassay, by Solomon Berson and Rosalyn Yalow in 1959.  
C. The isolation of proinsulin in 1967 by Donald Steiner’s group.  
D. Identification of specific insulin receptors by Pierre Freychet and 
colleagues in 1971, and  
E. The sequencing of the insulin receptor in 1985.  
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Mile stones in the management of diabetes have included,  
A. The development of long acting insulin preparations in 1936, 
B. The testing of sulfonylureas by Auguste Loubatieres in 1944.  
C. First therapeutic use of a biguanide (phenformin) by G. Ungar in 1957.  
D. Introduction in the late 1970’s of dry reagent test strips suitable for self 
monitoring of blood glucose, and  
E. Definitive proof from the diabetes control and complications trial 
(DCCT) published in 1993, that strict glycemic control could slow or 
prevent the development of diabetic microvascular complications. 
F. Emergence of Metformin in 1995. 
The classification of diabetes includes four clinical classes: 
 Type 1 diabetes (results from cell destruction,usually leading to absolute 
insulin deficiency) 
 Type 2 diabetes (results from a progressive insulin secretory defect on the 
Background of insulin resistance) 
 Other specific types of diabetes due to other causes,  
e.g., genetic defects in cell function,  
 Genetic defects in insulin action,  
11 
 
 Diseases of the exocrine pancreas (such as cystic fibrosis), drugs or 
chemical-induced diabetes (in the treatment of AIDS or after organ 
transplantation) 
 gestational diabetes mellitus (GDM) (diabetes diagnosed during 
pregnancy) 
Diagnosis of diabetes 
Criteria for the diagnosis of diabetes 
1. HbA1C -6.5%. The test should be performed in a laboratory using a 
method that is NGSP certified and standardized to the DCCT assay.* 
OR 
2. FPG -126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at 
          least 8 h.* 
OR 
3. Two-hour plasma glucose -200 mg/dl (11.1 mmol/l) during an OGTT. 
The test should be performed as described by the World Health 
Organization, using a glucose load containing the equivalent of 75 g 
anhydrous glucose dissolved in water.* 
OR 
4. In a patient with classic symptoms of hyperglycemia or hyperglycemic 
crisis, a random plasma glucose -200 mg/dl (11.1 mmol/l). 
*In the absence of unequivocal hyperglycemia, criteria 1–3 should be confirmed 
by repeat testing. 
12 
 
 
Categories of increased  risk for diabetes* 
FPG 100–125 mg/dl (5.6–6.9 mmol/l)[IFG] 
 2-h PG on the 75-g OGTT 140–199 mg/dl(7.8–11.0 mmol/l) [IGT] 
HbA1C 5.7–6.4% 
* Adopted from ADA 2010 guidelines. 
Criteria for testing for diabetes in asymptomatic adult individuals 
1. Testing should be considered in all adults who are overweight (BMI 25 
kg/m2) and have additional risk factors: 
 Physical inactivity 
 First-degree relative with diabetes 
 Members of a high-risk ethnic population (e.g., African American, Latino, 
Native American, Asian American, Pacific Islander) 
 Women who delivered a baby weighing 9 lb or were diagnosed with 
GDM 
 Hypertension (140/90 mmHg or on therapy for hypertension) 
 HDL cholesterol level 35 mg/dl (0.90 mmol/l) and/or a triglyceride level 
250mg/dl (2.82 mmol/l) 
 Women with polycystic ovary syndrome 
 HbA1C 5.7%, IGT, or IFG on previous testing 
 Other clinical conditions associated with insulin resistance (e.g., severe 
obesity,acanthosis nigricans) 
 History of CVD 
 
13 
 
 
2. In the absence of the above criteria, testing diabetes should begin at age 45 
years 
3. If results are normal, testing should be repeated at least at 3-year intervals, 
with consideration of more frequent testing depending on initial results.  
DIABETIC CARE 
Initial Evaluation 
A complete medical evaluation should be performed to classify the 
diabetes, detect the presence of diabetes complications, review previous 
treatment and glycemic control in patients with established diabetes, assist in 
formulating a management plan, and provide a basis for continuing care. 
Components of the comprehensive diabetes evaluation 
Medical history 
 Age and characteristics of onset of diabetes (e.g., DKA, asymptomatic 
laboratory finding) 
 Eating patterns, physical activity habits, nutritional status, and weight 
history; growth and development in children and adolescents 
 Diabetes education history 
14 
 
 Review of previous treatment regimens and response to therapy (HbA1C 
records) Current treatment of diabetes, including medications, meal plan, 
physical activity patterns,and results of glucose monitoring 
 DKA frequency, severity, and cause 
 Hypoglycemic episodes 
 Hypoglycemia awareness 
 Any severe hypoglycemia: frequency and cause 
 History of diabetes-related complications 
 Microvascular: retinopathy, nephropathy, neuropathy (sensory, 
including history of foot lesions; autonomic, including sexual 
dysfunction and gastroparesis) 
 Macrovascular: CHD, cerebrovascular disease, Pheripheral arterial 
disease.  
 Other: psychosocial problems, dental disease 
Physical examination 
 Height, weight, BMI 
 Blood pressure determination, including orthostatic measurements when 
indicated 
 Fundoscopic examination 
 Thyroid palpation 
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 Skin examination (for acanthosis nigricans and insulin injection sites) 
 Comprehensive foot examination: 
 Inspection 
 Palpation of dorsalis pedis and posterior tibial pulses 
 Presence/absence of patellar and Achilles reflexes 
 Determination of proprioception, vibration, and monofilament 
sensation 
Laboratory evaluation 
 HbA1C, if results not available within past 2–3 months 
 If not performed/available within past year: 
 Fasting lipid profile, including total, LDL- and HDL cholesterol and 
triglycerides 
 Liver function tests 
 Test for urine albumin excretion with spot urine albumin/creatinine ratio 
 Serum creatinine and calculated GFR 
 TSH in type 1 diabetes, dyslipidemia, or women over age 50 years 
Referrals 
 Annual dilated eye exam 
 Family planning for women of reproductive age 
 Registered dietician for MNT 
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 Dental examination 
Complications of Diabetes  
DIABETIC RETINOPATHY  
Diabetic retinopathy is the most frequent cause of blindness among adults 
aged 20-74 years. During the first two decades of disease, nearly all patients 
with type 1 diabetes mellitus and > 60% with type 2 diabetes mellitus have 
retinopathy. In type 2 diabetes mellitus, 21% of patients have retinopathy at 
first diagnosis. 
CLASSIFICATION (MODIFIED FROM AMERICAN ACADEMY OF 
OPTHALMOLOGY) 
Non Proliferative Diabetic Retinopathy (NPDR)  
1. Mild NPDR  
At least one retinal microaneurysm and one or more of the following : 
retinal hemorrhage, hard exudate, soft exudate.  
2. Moderate NPDR  
Hemorrhages or microaneurysms or both in atleast on quadrant and one or 
more of the following: soft exudates, venous beading and IRMA.  
3. Severe NPDR  
Hemorrhages or microaneurysms or both in all quadrants, venous 
beading in two or more quadrants , IRMA in at least one quadrant.  
17 
 
PDR  
1. Early PDR  
One or more of the following:  
 NVE  
 NVD  
 Vitreous or preretinal hemorrhage  
 NVE< ½ disc area.  
2. High risk PDR  
One or more of the following.  
 NVD > ¼- 1/
3 
disc area  
 NVD with vitreous or preretinal hemorrhage  
 NVE > ½ disc area. Preretinal or vitreous hemorrhage.  
3. Advanced PDR  
High risk PDR, traction retinal detachment involving macula or vitreous 
hemorrhage obscuring ability to grade NVD or NVE.  
 IRMA – Intraretinal microvascular abnormalities.  
 NVE – Neovascularisation elsewhere.  
 NVD – Neovascularisation disc.  
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Screening of Retinopathy1 
 Adults and children aged 10 years or older with type 1 diabetes should 
have an initial dilated and comprehensive eye examination by an 
ophthalmologist or optometrist within 5 years after the onset of diabetes. 
 Patients with type 2 diabetes should have an initial dilated and 
comprehensive eye examination by an ophthalmologist or optometrist 
shortly after the diagnosis of diabetes. 
 Subsequent examinations for type 1 and type 2 diabetic patients should be 
repeated annually by an ophthalmologist or optometrist. 
 Women with preexisting diabetes who are planning pregnancy or who 
have become pregnant should have a comprehensive eye examination and 
be counselled on the risk of development and/or progression of diabetic 
retinopathy. Eye examination should occur in the first trimester with close 
follow-up throughout pregnancy and for 1 year postpartum. 
Diabetic Nephropathy 
 Diabetes has become the most common single cause of end stage renal 
disease (ESRD) world wide1. About 20-30% of patients with type 1 or 
type 2 diabetes mellitus develop evidence of nephropathy, but in type 2 
diabetes a considerably smaller fraction of these progress to ESRD. 
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Category                                                    Spot collection 
                                                                      (g/mg.creatinine) 
Normal                                                                     <30 
Microalbuminuria                                                 30–299 
Macroalbuminuria(clinical)                                    >300 
Diabetic Neuropathy 
Classification 
SYMMETRIC ASYMMETRIC 
Distal sensorimotor Polyneuropathy Cranial Neuropathies 
Chronic Proximal motor neuropathy Limb Mononeuropathy 
Autonomic Neuropathy Radiculopathy & Plexopathies. 
FDA approved Drugs for Diabetic Neuropathy are Pregabalin & Duloxetine 
Other Drugs-Amitryptylin,Gabapentin,Imipramine. 
 
CARDIOVASCULAR DISEASE IN DIABETES1 
Cardiovascular disease incidence is increased in individuals with type 1 or 
type 2 diabetes mellitus. The American Heart Association recently designated 
type 2 diabetes mellitus as a coronary risk equivalent i.e. they have a similar 10 
year risk of MI, as those who have had a prior MI. In addition to coronary artery 
disease, cerebrovascular disease is increased in individuals with diabetes 
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mellitus (three fold increase in stroke). Proof that improved glycemic control 
reduces cardiovascular complications in diabetes mellitus is lacking. 
Summary of recommendations for adults with diabetes 
Glycemic control  
HbA1C  
Preprandial plasma glucose  
Postprandial plasma glucose  
 
< 7.0%  
90 – 130 mg/dl (5.0 – 7.2 mmol/l)  
< 180 mg/dl (< 10.0 mmol/l)  
Blood Pressure  < 130/80 mmHg  
Lipids  
LDL  
Triglycerides  
HDL  
 
< 100 mg/dl (<2.6 mmol/l)  
< 150 mg/dl (<1.7 mmol/l)  
> 40 mg/dl (> 1.1 mol/l)  
Key concepts in setting glycemic goals :  
• Goals should be individualized  
• Certain populations (children, pregnant women, and elderly) require special 
considerations  
• Less intensive glycemic goals may be indicated in patients with severe or frequent 
hypoglycemia  
• More stringent glycemic goals (i.e. a normal HbA1C < 6%) may further reduce 
complications at the cost of increased risk of hypoglycemia  
• Postprandial glucose may be targeted if HbA1C goals are not met despite reaching 
preprandial glucose goals.  
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MAGNESIUM 
MAGNESIUM is the fourth most common cation in the body and the 
second most common intracellular cation after potassium. The central role of 
magnesium within the chlorophyll molecule and as a cofactor for the enzymes in 
the 12- transphosphorylation reactions in photosynthesis makes it probably the 
most important inorganic element in the production of food and fossil fuel.
11
 In 
addition, it has a fundamental role as a cofactor in more than 320 enzymatic 
reactions involving energy metabolism and nucleic acid synthesis.
12
 
    Until recently, the function of magnesium in biological processes was 
largely ignored to the point where it was described as the ‘forgotten’ ion. In 
recent years, there has been an explosion of interest in the physiological and 
therapeutic properties of this essential element. It is involved in several 
processes, including hormone receptor binding and gating of calcium channels, 
transmembrane ion flux, regulation of adenylate cyclase, muscle contraction and 
neuronal activity, control of vascular tone, cardiac excitability and 
neurotransmitter release.
13,14
 Magnesium increases the body’s ability to utilize 
calcium, phosphorus, sodium,  potassium, vitamins C, E and B complex.
15
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       From a physiological perspective, magnesium is primarily regarded as a 
calcium antagonist, as most of its actions are linked to calcium. Calcium is an 
ideal agent for fast signal transduction and cell activation as cytosolic free 
calcium is only 1/10,000 of the corresponding extracellular species, traditionally 
called ionized calcium.  
    Magnesium, on the other hand, having a slight gradient over the plasma, plays 
the complementary role of a more long-term regulatory element. Alterations of 
intracellular or extracellular magnesium concentration may affect cell function 
through its effect on calcium handling. Most of the intracellular magnesium is 
located within the mitochondria apparently because magnesium binds strongly 
with ATP. In general, the more metabolically active the cell is, the higher is its 
magnesium content. Levels of magnesium in the plasma of healthy people are 
remarkably constant, being on an average of 1.3–2.4 mg/dl (0.7–1.0 mmol/l).   
       It has been estimated that refining and processing of food causes a 
substantial loss of magnesium. For example, the refining and processing of 
wheat to flour, rice to polished rice and corn to starch depletes magnesium by  
82, 83 and 97% respectively.
 16
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Normal Mg Metabolism 
Gastrointestinal Metabolism 
        On an average diet, 250 to 350 mg of Mg is consumed daily. Twenty-five 
to 60% of dietary Mg is absorbed in the gastrointestinal tract. Gastrointestinal 
absorption occurs predominantly in the small intestines via paracellular simple 
diffusion at high intraluminal concentrations and active transcellular uptake via 
Mg-specific transporters at low concentrations.
21
 Active intestinal Mg 
absorption is presumed to involve transient receptor potential channel melastatin 
6 (TRPM6), which is expressed along the brush border membrane of the small 
intestine.
18
 Mutations of TRPM6 have been reported to be associated with 
hypomagnesemia with secondary  
hypocalcemia.
19,20
 
 
Renal Metabolism 
 Glomerular Filtration.  
            Approximately 70 to 80% of plasma Mg is ultrafilterable in the ionic 
form (70 to 80%) and complexed with anions such as phosphate, citrate, and 
oxalate (20 to 30%).
21,22
 The ultrafilterability of Mg depends on glomerular 
filtration, volume status, various metabolic states that would enhance the 
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selection for ionized Mg (e.g., acidemia, reduced serum content of negatively 
charged species), and the integrity of the glomerular basement membrane. 
 Proximal Tubules.  
            Once Mg is filtered through the glomerulus, 15 to 25% is reabsorbed in 
the proximal tubules. Reabsorption at the proximal tubule is mainly passive and 
proportional to sodium and water reabsorption, although at a lower rate.
22
 
Loop of Henle.  
           Approximately 65 to 75% of the Mg filtered load is reabsorbed via the 
paracellular pathway in the thick ascending limb of the loop of Henle (TAL). 
Paracellular Mg reabsorption at this nephron segment has been suggested to be 
facilitated by claudin 6, also known as paracellin 1. Paracellin 1 is a tight 
junction protein whose mutation is associated with severe hypomagnesemia with 
hypercalciuria and nephrolithiasis.
23,24
 Parathyroid hormone, calcitonin, 
glucagon, and antidiuretic hormone have been suggested to enhance Mg 
transport in the TAL via the second messenger Cyclic AMP. Insulin also has 
been implicated to play a role at this nephron segment by increasing the 
favourable transepithelial potential difference for Mg reabsorption. 
Distal Convoluted Tubules. 
         The distal convoluted tubule (DCT) reabsorbs approximately 5 to 10% of 
the filtered Mg via an active and regulated transcellular pathway. Although this 
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is a low percentage of the filtered Mg load, it represents 70 to 80% of Mg that is 
delivered from the TAL. In addition, because a negligible amount of Mg is 
reabsorbed distal to this segment, Mg reabsorption at the DCT is of great 
importance because it determines the final urinary Mg concentration.
21
 
Recently, Mg reabsorption at the DCT was shown to occur via the transient 
receptor potential channel melastatin TRPM6. It has been postulated that upon 
entry into the cells, Mg binds to divalent-binding proteins such as parvalbumin 
or calbindin-D28K for transport across the cell to the basolateral membrane, 
where Mg is taken into the interstitium by a basolateral Na2+/Mg2+ exchanger 
and/or ATP dependent Mg pump.
22,
 
       It is interesting that the regulation of magnesium reabsorption at the DCT 
was studied extensively before the actual identification of TRPM6. Peptide 
hormones such as parathyroid hormone (PTH), calcitonin, glucagon, and 
vasopressin all have been implicated. The mediating mechanisms are unknown 
but seem to involve, in part, stimulation of cAMP release and activation of 
protein kinase A, phospholipase C, and protein kinase C. Insulin also has been 
suggested to enhance intracellular Mg uptake, presumably via tyrosine kinase. 
Moreover, insulin may stimulate the production of cAMP and potentiate Mg 
uptake via other cAMP-dependent hormones, including PTH. In addition, the 
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Ca/Mg sensing receptor on the basolateral side may modulate hormone-
stimulated Mg transport through G-protein coupling. Finally, low 
dietary Mg intake and estrogens have been shown to upregulate renal TRPM6 
expression and reduce urinary Mg excretion.
29
 
Dietary Reference Intakes for Magnesium 
 Recommendations for magnesium are provided in the dietary reference intakes 
(DRI’s) developed by the Food and Drug Administration (FDA).
  
Recommended Dietary Allowances (RDA) for magnesium are as per the table. 
AGE IN YRS MALE FEMALE 
1-3 80 80 
4-8 130 130 
9-13 240 240 
14-18 410 360 
19-30 400 310 
31+ 420 320 
(Magnesium values in mg/day). 
 During pregnancy 350mg/day  
 During lactation 310mg/day 
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Hypermagnesemia  
Hypermagnesemia is rarely seen in the absence of renal insufficiency, as 
kidneys can excrete large amounts of magnesium (up to 250 mmol/d).
 30
 
Causes of hypermagnesemia  
 Impaired magnesium excretion  
Renal failure  
Familial hypocalciuric hypercalcemia  
 Excessive magnesium intake  
Cathartics  
Antacid preparations  
Parenteral magnesium administration (eg.magnesium sulfate in PIH)  
 Rapid magnesium mobilisation from soft tissues  
Trauma  
Extensive burns  
Shock, sepsis  
 Other disorders  
Adrenal insufficiency  
Hypothyroidism  
Hypothermia  
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Clinical features  
The most prominent clinical manifestation of hypermagnesemia are 
vasodilation and neuromuscular blockade, which appear at serum magnesium 
concentrations > 4.8 mg/dL (>2mmol/L). Hypotension, refractory to 
vasopressors and volume expansion, may be an early sign. Lethargy and 
weakness may progress to respiratory failure, paralysis and coma with 
hypoactive tendon reflexes (at serum magnesium levels > 4 mmol/L). 
Gastrointestinal hypomotility or ileus may occur. Prolongation of PR, QRS 
intervals, heart blocks and, at serum magnesium levels approaching 10 mmol/L, 
asystole.  
Treatment  
Generally involves identifying and avoiding the source of magnesium. 
Vigorous intravenous hydration and hemodialysis may be necessary. Calcium, 
given intravenously in doses of 100-200 mg over 1 to 2 hrs provides temporary 
improvement.  
Hypomagnesemia  
Hypomagnesemia signifies substantial depletion of body magnesium 
stores   (0.5 to 1 mmol/Kg). Hypomagnesemia has varied etiology. Dietary 
magnesium deficiency is unlikely except in the setting of alcoholism.
 30
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Causes of Hypomagensemia
30
 
I. Impaired intestinal absorption  
Primary infantile hypomagnesemia  
Malabsorption syndromes  
Vitamin D deficiency.  
II. Increased intestinal losses  
Protracted vomiting / diarrhea  
Intestinal drainage, fistulae  
III. Impaired renal tubular reabsorption  
A. Genetic magnesium wasting syndromes.  
Gitelman syndrome  
Bartter syndrome  
Na-K ATPase g-subunit mutations 
B. Acquired renal disease  
Tubulointerstitial disease  
Post obstruction /ATN (diuretic phase)  
Renal transplantation.  
C. DRUGS  
Ethanol  
Diuretics (loop, thiazide and osmotic)  
Cisplatin, cyclosporine  
Aminoglycosides, Amphotericin B  
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IV. Metabolic causes  
Hyperaldosteronism  
SIADH  
Diabetes mellitus  
Metabolic acidosis  
V. OTHERS  
Pancreatitis  
Excessive sweating  
Osteoblastic metastases  
Several genetic magnesium wasting syndromes are explained, but are 
extremely rare. Prolonged nasogastric suction, parenteral fluids, infectious 
diarrhea, steatorrhoea, inflammatory bowel disease may cause 
hypomagnesemia.
31 
Magnesium deficiency is especially common in patients 
receiving furosemide diuretic.
32
 
Frequency  
Hypomagnesemia is a common entity occurring in up to 12% of 
hospitalized patients.
33 
The incidence rises to as high as 60% in patients in 
intensive care settings in which nutrition, diuretics, hypoalbuminemia, and 
aminoglycosides may play important roles.
34  
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Risk of incidence is as follows:
35
 
2% in general population.  
10 – 20% in hospitalized patients.  
50 – 60% in ICU patients.  
25% in diabetic outpatients.  
Sex: Incidence is equal in males and females.  
Clinical features.
2,36
 
History  
 Clues to the presence of hypomagnesemia can be found by obtaining 
history of potential causes.  
 Historical complaints related to hypomagnesemia are nonspecific.  
 Patients may report weakness, muscle cramping or rapid heartbeats.  
 Altered mental status (irritability, apathy, psychosis, delirium) may be 
present in severe cases. Less severe cases may result in vertigo, ataxia, 
depression and seizure activity.  
Physical signs  
Symptoms and signs appear only when serum magnesium concentrations 
are <1.2 mg/dL (0.5 mmol/L). The primary clinical findings are neuromuscular 
irritability, CNS hyperexcitability, and cardiac arrhythmias.
37
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Signs  
 Hyperactive deep tendon reflexes.  
 Muscle cramps.  
 Trousseau and Chvostek signs  
 Dysphagia due to esophageal dysmotility  
 Irritability/ disorientation  
 Ataxia, nystagmus or seizures (at levels <0.8 mg/dl) Paroxysmal atrial 
and ventricular dysrhythmias.  
 
ECG  
Magnesium depletion can induce changes in the electrocardiogram. 
Findings in hypomagnesaemia are nonspecific. Modest magnesium depletion 
(1.2 to 1.7 mg/dl) leads to widening of QRS complex with peaking T-waves, 
while more severe magnesium depletion (<1.2 mg/dl) is associated with 
prolongation of PR interval, progressive widening of QRS complex, flattening / 
inversion of T-waves and U waves.
38
 
Cardiac arrhythmias may occur including sinus tachycardia, other 
supraventricular tachycardia and ventricular arrhythmias.  
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Lab Studies  
The serum magnesium level is not a reliable determinant of total body 
magnesium depletion, because only a small fraction of magnesium in the body is 
extracellular. Nevertheless, a deficiency of magnesium is clearly present if 
serum level is low.
39
 
Serum magnesium levels may be estimated by several methods.  
• Neutron activation analysis  
• Atomic absorption spectrometry  
• Ion selective electrodes (ISE)  
• Equilibrium dialysis  
• Calmagite dye method.  
Calcium, potassium and phosphorous levels must be assessed.  
BUN and creatinine levels.  
Blood glucose level.  
Treatment  
The route of magnesium repletion varies with severity of the clinical 
manifestations. As an example, the hypocalemic-hypomagnesemic patient with 
tetany or the patient with hypomagnesemic ventricular arrhythmias should 
receive 50 mEq of IV magnesium given slowly over 8 to 24 hours. This dose 
34 
 
can be repeated as necessary to maintain plasma magnesium concentration 
above 1.0 mg/dl.
40
 
Oral replacement should be given in less critical patients, preferably with 
a sustained release preparation. There are several such preparations available – 
Slow Mag (magnesium chloride) and MagTab-SR (Magensium lactate). These 
preparations provide 60-84mg (2.5 to 3.5 mmol) per tablet. Six to eight tablets 
should be taken daily in divided doses for severe magnesium depletion 
(<1.2mg/dL). Two to four tablets are sufficient for milder disease. The 
underlying disease should be corrected, if possible. It includes discontinuation of 
diuretic therapy, addition of potassium sparing diuretic in those who cannot 
discontinue diuretic therapy, treatment of chronic diarrhea etc. 
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MAGNESIUM AND DIABETES 
Magnesium deficiency in diabetes 
Magnesium ion has a fundamental role in carbohydrate metabolism in 
general, and in the action of insulin in particular.Magnesium is a cofactor in the 
glucose transporting mechanism of the cell membrane and various enzymes in 
carbohydrate oxidation. Cellular magnesium seems to play an important role in 
glucose metabolism as it is a critical cofactor for the activities of various 
enzymes involved in glucose oxidation and may play a role in the release of 
insulin. Magnesium is involved at multiple levels in insulin secretion, binding 
and activity.
 41
 It is also involved in many phosphorylation reactions and is a 
cofactor for ATPase and adenylate cyclase enzymes. Magnesium deficiency has 
recently been proposed as a novel factor implicated in the pathogenesis of 
diabetic complications. 
Recognizing the signs of diabetes associated magnesium deficiency is 
important  because the deficiency can occur long before it is reflected by serum 
values. 
Diabetes mellitus has been suggested to be the most common metabolic 
disorder associated with magnesium deficiency, having 25 to 39% prevalence.
 42
 
Recent evidences suggest that insulin can increase free magnesium entry into the 
cell. Glycemic control in patients with type-2 diabetes, however, may not correct 
36 
 
low magnesium concentration, suggesting that other factors may regulate 
magnesium levels in diabetic patients.
 43
 
HypoMagnesemia in Type 2 Diabetes 
Causes of hypomagnesemia in diabetes mellitus 
Hypomagnesemia in the patient with diabetes may result from poor oral intake, 
poor gastrointestinal absorption, and enhanced renal Mg excretion . 
Gastrointestinal Causes 
Diabetic autonomic neuropathies that may reduce oral intake and 
gastrointestinal absorption include esophageal dysfunction, gastroparesis, and 
diarrhea.
 44
 Whether gastrointestinal Mg absorption via TRPM6 is reduced in the 
patient with diabetes is not known. 
Renal Causes 
Enhanced Filtered Load.   
In the patient with diabetes, the  ultrafilterable Mg load may be enhanced 
by glomerular hyperfiltration, recurrent excessive volume repletion after 
hyperglycemia-induced osmotic diuresis, recurrent metabolic acidosis associated 
with diabetic ketoacidosis, and hypoalbuminemia.
45 
 The last two conditions 
may increase the serum ionized Mg fraction and, hence, ultra filterable Mg load 
and subsequent urinary loss. In addition, it is conceivable that significant 
microalbuminuria and overt proteinuria among patients with diabetic 
37 
 
nephropathy may contribute to renal Mg wasting as a result of protein-bound 
magnesium loss. 
Enhanced Tubular Flow. Overly aggressive volume reexpansion and 
glomerular hyperfiltration also may induce renal Mg wasting at the proximal 
tubule and TAL, independent of the filtered load. Because Mg reabsorption 
parallels sodium reabsorption in the proximal tubules, volume expansion can 
decrease both sodium and Mg reabsorption at this level. Similarly, a high tubular 
flow through the TAL may reduce Mg reabsorption at this segment.
45
 
Reduced Tubular Reabsorption. Because insulin has been implicated in 
enhancing Mg reabsorption at the TAL, insulin deficiency or resistance in the 
diabetic state can promote Mg wasting at this nephron segment.
46
 The 
expression of paracellin 1 in TAL, however, has not been shown to be increased 
in diabetic rats.
47
  
In the same diabetic rat model, Lee et al.
47
 revealed that TRPM6 
expression in the DCT is not reduced but rather enhanced.This is thought to be a 
compensatory mechanism for the increased Mg load that is delivered to the DCT 
or blunted activity of the TRPM6 channel in the diabetic state. Accordingly, 
despite the increase in TRPM6 expression, overall renal Mg wasting is 
observed. 
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Metabolic Disturbances: 
       Various metabolic disturbances that are associated with diabetes also have 
been suggested to promote urinary Mg excretion. 
 Hypokalemia: At the TAL segment, hypokalemia may reduce Na-K-2Cl        
co-transport activity, the associated potassium extrusion through the 
potassium channel ROMK, and resultant diminution of the favorable 
transmembrane voltage that is required for paracellular Mg reabsorption. 
In addition, there is evidence to suggest that cellular potassium depletion 
may diminish Mg reabsorption at the DCT by yet unclear mechanisms.
48
 
 Hypophosphatemia: Both micropuncture studies in phosphate-depleted 
dogs and in vitro studies involving phosphate depleted mouse DCT cells 
have demonstrated reduced Mg uptake.
49,50
 Phosphate-induced reduction 
in cellular uptake of Mg is believed to be a posttranslational effect 
because the alteration in Mg uptake could be observed within 30 min of 
phosphate depletion. 
 Metabolic Acidosis: In addition to its role in increasing serum ionized 
Mg concentration and, hence, ultrafilterable Mg load for renal excretion, 
metabolic acidosis has been suggested to enhance protonation of the Mg 
channel in the DCT and subsequent inhibition of cellular Mg uptake.
51
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More recently,  Nijenhuis et al.
52
 showed  reduced expression of TRPM6 
with induced chronic metabolic acidosis in mice. 
Insulin Deficiency and/or Resistance. As previously discussed, insulin 
deficiency or resistance may exacerbate renal Mg wasting because insulin has 
been shown to have antimagnesiuric effects in both the TAL and the DCT.
 54
 
Use of Diuretics 
The common use of diuretics among patients with diabetes also may 
contribute to magnesiuria. The degree of magnesiuria is traditionally thought to 
be lower for thiazides compared with loop diuretics.
55,56
 This difference has been 
explained by the site of action of the two types of diuretics because a smaller 
amount of intraluminal Mg is available for wasting at the DCT compared with 
that at the loop of Henle. In addition, inhibition of  the Na_-Cl_ co-transporter 
by thiazides has been suggested to induce hyperpolarization of the DCT plasma 
membrane and, hence, a more favorable transmembrane electrical gradient for 
Mg reabsorption.
58
 Recently, reduced TRPM 6 expression and enhanced 
magnesiuria  were shown in mice given chronic thiazide therapy.
59
Given these 
observations and the lack of good direct comparative data between the two 
classes of diuretics, it must be assumed that significant magnesiuria may occur 
with either. 
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Others 
Finally, the more common use of antibiotics and antifungals such as 
aminoglycosides and amphotericin in patients with diabetes may also contribute 
to renal Mg wasting.
 60
 
The role of magnesium in insulin action  
Magnesium is involved in multiple levels in insulin secretion, binding and 
activity. Magnesium is a critical cofactor of many enzymes in carbohydrate 
metabolism. Cellular magnesium deficiency can alter the activity of the 
membrane bound Na- K- ATPase, which is involved in the maintenance of 
gradients of sodium and potassium and in glucose transport. Low levels of 
magnesium can reduce secretion of insulin by the pancreas.
 61
 
In addition to these effects of magnesium, magnesium deficiency has been 
shown to promote insulin resistance in multiple studies. In isolated soleus 
muscle, magnesium deficiency inhibits both basal and insulin-stimulated 
glucose uptake. This insulin resistance is a post receptor defect and may be 
linked to calcium mediation of insulin signal.
67 
In diabetics, there is a direct 
relationship between serum magnesium level and cellular glucose disposal, that 
is independent of insulin secretion. This change in glucose disposal has been, 
shown to be related to increased sensitivity of the tissues to insulin in the 
presence of adequate magnesium levels.
 62
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In a recent study, the cellular uptake of magnesium, which is normally 
stimulated by insulin, was shown to be attenuated in diabetics.
 63 
There is also 
evidence that magnesium deficiency itself produces insulin resistance. Nadler et 
al.
8 
studied 16 non diabetic subjects and found that insulin sensitivity fell after 
induction of magnesium deficiency.  
Likewise, elderly nondiabetic subjects were shown to have improved 
glucose handling, when they received magnesium supplements for 4 weeks.
64 
There was a direct relationship between intracellular magnesium concentration 
and glucose metabolism, thus implicating magnesium deficiency in the insulin 
resistance of aging. In non diabetic obese subjects, insulin resistance was found 
along with low magnesium levels, when compared with non obese subjects, 
again highlighting the association between hypomagnesemia and insulin 
resistance.
65 
 
An intriguing theory, suggested by Tonyai, et al.
66 
is that a low 
erythrocyte magnesium content can alter membrane viscosity, and this may 
impair the interaction of insulin with its receptor on the membrane. 
 Paolisso, et al.
64 
were able to correct the increase in erythrocyte 
microviscosity with long-term magnesium administration. 
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Role of magnesium deficiency in diabetic end organ damage  
Magnesium deficiency has been found to be associated with diabetic 
microvascular disease. Hypomagnesemia has been demonstrated in patients with 
diabetic retinopathy, with lower magnesium levels predicting a greater risk of 
severe diabetic retinopathy.
10 
Magnesium depletion is also found to play a role 
in the pathogenesis of diabetic polyneuropathy. Corsonello, et al have reported 
an association between diabetic nephropathy and magnesium depletion. 
Microalbuminuria and clinical proteinuria, as well as poor glycometabolic 
control and hypertriglyceridemia, are associated to relevant alterations in serum 
ionized magnesium. Magnesium depletion has been associated with multiple 
cardiovascular implications: arrhythmias, vasospasm, hypertension and platelet 
activity.
69,70
 
Three exciting theories link diabetes and its vascular complications to 
hypomagnesemia: the inositol transport theory, the ionic hypothesis of metabolic 
disease and oxidative stress theory.  
Grafton, et al
4 
have focussed on the inositol transport theory. It has been 
one of the favored explanations for the origin of diabetic complications. The 
theory suggests that hyperglycemia induces increased activity of the enzyme 
aldose reductase, which leads to the intracellular accumulation of sorbitol. The 
accumulated sorbitol inhibits transport of inositol, leading to a decrease in 
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intracellular inositol and inhibition of the Na –K- ATPase activity. The data of 
Grafton, et al show that hypomagnesaemia causes a decrease in the affinity of 
the inositol transport protein for inositol, leading to a two fold reduction in rate 
of inositol transport and accelerated development of diabetic complications.  
The association between magnesium deficiency, essential hypertension, 
insulin resistance, hyperinsulinemia, and ischemic heart disease (Reaven-Modan 
Syndrome) may be explained by the ionic hypothesis of cardiovascular and 
metabolic disease, proposed by Resnick.
68 
Suppression of intracellular free 
magnesium and an increase of intracellular free calcium are linked in these 
varied biologic processes: hypertension, decreased insulin secretion, and insulin 
resistance. Therefore, Resnick proposed that the ‘primary’ defect present in all 
organ systems is an abnormality of cellular ion handling. Magnesium deficiency 
would be the link, since its role in maintaining cellular pumps necessary for 
peripheral vascular tone (Na-K-ATPase and calcium activated K+ channels) 
would be diminished. Indeed, magnesium deficiency may lead to a reduction in 
insulin action by increasing free intracellular calcium levels.  
Diabetes is a state of increased free radical activity. Lipid peroxidation of 
cellular structures, a consequence of free radical activity, is thought to play an 
important role in aging, atherosclerosis and late diabetic complications. In recent 
years, there has been a growing interest in magnesium and its correlation with 
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oxidative states. Weglicki, et al have proposed that during magnesium 
deficiency, natural antioxidant defences present in mammalian tissues against 
oxidative stress may be compromised. Magnesium deficiency has been shown to 
impair functions of natural antioxidants such as glutathione, ascorbic acid and 
Vit.E. 
Management of Hypomagnesemia in Type 2 Diabetes 
   Because the literature suggests adverse outcomes in association with 
hypomagnesemia in patients with type 2 diabetes, measures to minimize this 
abnormality are warranted 
Suggested management of hypomagnesemia in patients with type 2 diabetes 
Increase Mg intake 
  Dietary consult   
   High Mg-containing food types 
      soya products, legumes, and seeds such as almonds and cashews, whole         
grains and fruits and vegetables such as spinach, okra, Swiss chard, dried 
apricots, and avocados 
Control of diabetic gastroparesis 
      Eat multiple small meals instead of two to three large meals per day 
      Tight glucose control 
      Use of prokinetic medications to enhance gastric motility 
45 
 
     Others: pyloric botulinum toxin injection, enteric feeding, gastric pacing
71,73
 
 
Decrease gastrointestinal loss (diarrhea) 
     Trial of soluble fiber 
     Regular effort to move bowels 
     Trials of gluten-free diet, lactose restriction 
     Others: cholestyramine, clonidine, somatostatin analog, supplemental   
     Pancreatic enzyme, and antibiotics such as metronidazole
44
 
Decrease renal Mg loss 
   Decrease filtered load 
   Use angiotensin-converting enzyme and/or angiotensin receptor blockers 
   Tight glycemic control
44
 
   Avoid excessive volume replacement during periods of hyperglycemia 
Increase renal reabsorption 
    Tight glycemic control; measures to decrease insulin resistance (exercise) 
    Replacement of phosphate and potassium as needed                            
    Replacement of diuretic-induced magnesiuria (based on  24-h urine output). 
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MATERIALS AND METHODS 
This study was undertaken with the aim to determine serum magnesium 
level in patients with Type 2 Diabetes Mellitus without it's associated 
complications and Type 2 Diabetes mellitus patients with its various macro and 
microvascular complications namely Coronary atherosclerosis, Hypertension, 
retinopathy, neuropathy and nephropathy respectively. 
STUDY POPULATION: 
     The study was conducted at Government Rajaji Hospital, Madurai on total of 
120 subjects of age group 40 - 70 years; of whom 20 were apparently healthy 
and served as control.  
Inclusion criteria  
 All cases of type 2 diabetes mellitus coming to Dept of 
Diabetology, GRH, Madurai. During the period of April 2011 to 
October 2011   
Exclusion criteria  
1. Patients with chronic renal failure.  
2. Acute myocardial infarction in last 6 months.  
3. Patients on diuretics.  
4. Patients with history of alcohol abuse.  
5. Patients receiving magnesium supplements or magnesium containing 
antacids.  
47 
 
6. Malabsorption or chronic diarrhea.  
Data collection  
The 100 type 2 diabetics (with median diabetic history of 6.25 years) were 
included in the study. Detailed history – including duration of diabetes, 
treatment mode, symptoms suggestive of diabetic neuropathy, associated 
diseases such as hypertension and ischemic heart disease was obtained, as per 
the proforma. Followed by physical and neurological examination, and ECG. 
Retinopathy was assessed by direct opthalmoscopy. Blood samples were 
collected for measurement of fasting blood glucose and serum magnesium.  
Blood urea, serum creatinine and 24 hour urinary albumin were estimated. 
Serum magnesium was estimated by Calmagite dye method. HbA1C estimation 
was carried out by a modified calorimetric method.  
Calmagite dye method for quantitative estimation of serum magnesium Test 
principle: 
 Under alkaline conditions, magnesium ions react with calmagite dye to 
produce a red complex which is measured spectrophotometrically at 530 nm. 
Intensity of the colour produced is directly proportional to magnesium 
concentration in the serum. To eliminate the interference of calcium during 
estimation, EDTA is included in the reagent. Heavy metal interference is 
48 
 
prevented by the presence of cyanide and a surfactant system is included to 
prevent protein interference.   
Magnesium + Calmagite               Red coloured complex 
Test procedure:  
Three test tubes labeled Blank, Standard and Test are prepared as in table. 
Three test tubes are incubated at room temperature (22-28ºC). The 
absorbance of Test (A
T
), Standard (A
S
) and Blank (A
B
) are read at 530nm in 
spectrophotometer. Magnesium concentration is calculated by the following 
formula.  
Magnesium concentration (mEq/L) = (A
T
-A
B 
/ A
S
-A
B
) x 2  
Serum magnesium concentration is expressed in mg/dl by linearity of 1 
mEq/L = 1.2 mg/dl.  
Subsequently patients were divided into three groups based on their serum 
magnesium concentrations defined as follows: Normal, 1.3 to 2.5 mg/dl, low 
In test tubes 
 
Blank 
 Standard Test 
Calmagite reagent 
 1.0ml 1.0ml 1.0ml 
Standard sample 
 - 10ml - 
Patient’s sample 
 - - 10ml 
Distilled water 
 10ml - - 
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<1.3mg/dl. Patients were also categorized on the basis of duration of diabetes, 
presence of ischemic heart disease or hypertension, mode of treatment, 
presence/absence of retinopathy, neuropathy and nephropathy, and glycemic 
control (FBS and HbA1C). Patients with diabetic retinopathy were further 
classified as those with nonproliferative diabetic retinopathy (NDPR) and those 
with proliferative diabetic retinopathy (PDR). Diabetic nephropathy was graded 
depending on 24 hour urinary excretion of albumin as follows: No nephropathy, 
< 30mg/24hour, microalbuminuria 30 – 299mg/24hour and macroalbuminuria 
(clinical proteinuria) > 300 mg/24hour.  
Statistical Tools ( To be included at the end of Materials and Methods)  
The information collected regarding all the selected cases were recorded 
in a Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2010) developed by Centre for 
Disease Control, Atlanta.  
 Range, frequencies, percentages, means, standard deviations, chi square 
and 'p'  values were calculated using this software. Kruskul Wallis chi-square  
test was used to test the significance of difference between quantitative variables 
and Yate’s chi square test for qualitative variables. A 'p' value less than 0.05 is 
taken to denote significant relationship. 
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RESULTS 
  AGE DISTRIBUTION  (Table 1): 
 
 
  
 
 
 
 
 
The 100 cases included in the study had an age of 57.1 +5.8 years. The 20 
control cases had an age of 54.96 +6.7 years. There was no significant difference 
in the age composition of the two groups compared. ( p > 0.05). 
Table 2 : Sex distribution 
 
Sex 
Study group Control group 
No. % No. % 
Male 61 61 13 65 
Female 39 39 7 35 
Total 100 100 20 100 
‘p’ 0.7893  
Not significant 
 
 61% of the study group and 65% of the control group were males. The sex 
composition of the two groups was  not significantly different ( p = 0.7893). 
Age group Cases in 
Study 
group 
Control group 
No. % No. % 
40 – 50 years 16 16 6 30 
51- 60 years 66 66 10 50 
61-70 years 18 18 4 20 
Total 100 100 20 100 
Range 40-70 years 43-67 years 
Mean 57.1 54.9 years 
SD 5.8 years 6.7 years 
‘p’ 0.2392  
Not significant 
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Table 3 : Fasting blood sugar in diabetics & control group 
 
Fasting blood sugar 
Cases in 
Study group Control group 
No. % No. % 
Controlled 41 41 20 100 
Uncontrolled 59 59 - - 
Total 100 100 20 100 
Range 100-155 
mg/dl 
96-110 mg/dl 
Mean 133.0 mg/dl 101.6 mg/dl 
SD 13.6 mg/dl 3.9 mg/dl 
‘p’ 0.0001  
Significant 
 
 In the study group, the fasting blood sugar values were 133 +13.6 mg/dl. 
These values were significantly higher than the values of the control group 
(101.6+3.9). 
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Table 4 : Magnesium levels in diabetic and control group 
 
Magnesium 
Cases in 
Study group Control group 
No. % No. % 
Hypo magnesemia (< 1.3) 39 39 - - 
Normal ( >  1.3) 61 61 20 100 
Range 0.6-2.2 1.3 – 2.4 
Mean 1.42 1.94 
SD 0.37 0.27 
‘p’ 0.0001  
Significant 
 
 The magnesium values of the diabetic group (1.42 +0.37) and the control 
group (1.94 +0.27) were statistically significant ( p = 0.0001). In control group 
no hypomagnesemia was noticed .   
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Table 5. Characteristics of study population 
Characteristics Numbers 
 
No. Of subjects 
 
Mean Age in years (range) 
 
Males 
 
Females 
 
Mean Duration of diabetes in 
years(range) 
 
Medications 
       OHA 
       OHA+Insulin 
 
Comorbidity 
       Hypertension 
       IHD 
 
Diabetic complications 
      NPDR 
      PDR 
 
Diabetic nephropathy 
     Micro albuminuria 
     Macro albuminuria 
 
Diabetic neuropathy 
 
Poor glycemic control ( HbA1c > 7) 
 
 
100 
 
57.1 (40-70 years) 
 
61 
 
39 
 
6.25(3-15 years) 
 
 
 
90 
10 
 
 
20 
8 
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B : RELATIONSHIP BETWEEN SERUM MAGNESIUM  AND OTHER 
VARIABLE IN  
DIABETIC (STUDY) CASES 
Table 6 : Age and hypomagnesemia in DM cases 
 
Age group 
Magnesium  
Mean 
+SD 
Hypo Normal 
No. % No. % 
40 – 50 years (16) 3 18.8 13 81.3 1.61 +0.38
51-60 years ( 66) 24 36.4 42 63.6 1.43 +0.37
61-70 years ( 18) 12 66.7 6 33.3 1.24 +0.27
‘p’ 0.177  
Not Significant 
 
The relationship between age and incidence of hypomagnesemia in diabetic 
cases was statistically not significant ( p > 0.05). 
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Table 7 : Sex and hypomagnesemia in diabetic cases 
 
Sex 
No. of 
cases 
Magnesium 
Hypo Normal Mean 
+SD No. % No. % 
Male  61 23 37.7 38 53.5 1.39 
+0.35 
Female 39 16 41 23 79.3 1.47 
+0.35 
‘p’ 0.268  
Not Significant 
 
Prevalence of hypomagnesemia in diabetic males and females were 23%&16% 
respectively.there is no statistical significance between sex of the patient and 
hypomagnesemia. 
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Table 8 : Duration of diabetes and magnesium 
 
Magnesium levels 
Duration of diabetes (years) 
Mean SD 
Hypo magnesia 7.79 2.13 
Normal cases 6.28 1.66 
‘p’ 0.0006  
Significant 
 Duration of diabetes was 7.79. +2.13 years in hypomagnesemia cases 
and  6.25 +1.66 years in cases with normal magnesium values. This difference 
was statistically significant ( p = 0.0006). 
 
Table 9 : Treatment and magnesium levels in diabetic cases 
 
Treatment 
No. of 
cases 
Magnesium 
Hypo 
<1.3mg 
Normal  
Mean 
+SD No. % No. % 
OHA 90 34 37.8 56 62.2 1.42 
+0.37 
OHA + I 10 5 50 5 50 1.42 +0.4 
‘p’ 0.9028  
Not significant 
 
 There was no significant relationship between type of treatment given 
and prevalence of hypomagnesemia in diabetic cases. ( p > 0.05). 
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Table 10 : Relationship between fasting blood sugar and hypomagnesemia 
in diabetic cases 
 
 
Fasting blood sugar 
 
No.of 
cases 
Magnesium 
Hypomagnesmia 
<1.3mg /dl  
Normal 
No. % No. % 
Controlled(FBS<130) 41 9 22 32 78 
Uncontrolled(FBS>130) 59 30 50.8 29 49.2 
‘p’ 0.0068  
Significant 
 When fasting blood sugar was controlled, the incidence of 
hypomagnesemia was only 22% in diabetic cases. But when it was 
uncontrolled, this increased to 50.8%. This relationship was statistically 
significant ( p < 0.05). 
Table 11 : HbA1C values and hypomagnesemia in diabetic cases 
 
HbA1C values 
 
No.of 
cases 
Magnesium 
Hypo magnesemia 
<1.3mg / dl 
Normal 
No. % No. % 
Normal(HbA1c<7) 30 4 13.3 26 86.7 
Abnormal(HbA1c>7) 70 35 50 35 50 
‘p’ 0.0013  
Significant 
 
 Hypomagnesemia was present in 13.3% of cases with normal HbA1C 
values and in 50% of cases with abnormal HbA1C values. This was 
statistically significant  ( p = 0.0013). 
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Table 12 : Ischemic Heart Disease and Magnesium in diabetic cases 
 
IHD 
 
No. of 
cases 
Magnesium 
Hypo Normal Mean 
+SD No. % No. % 
Present 8 3 37.5 5 62.5 1.4 +0.33 
Absent 92 36 39.1 56 60.9 1.43 
+0.37 
‘p’ 0.9743  
Not significant 
 
 The association between incidence of IHD and hypomagnesemia was not 
statistically significant in diabetic cases ( p = 0.9743). 
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Table 13 : Hypertension and magnesium in diabetic cases 
 
Hypertension 
No. of 
cases 
Magnesium 
Hypo 
 <1.3 mg /dl 
Normal Mean 
+SD 
No. % No. % 
Present 20 4 20 16 80 1.39 
+0.38 
Absent 80 35 43.8 45 56.3 1.58 +0.3 
‘p’ 0.22  
Not Significant 
 
 The relationship between hypertension and hypomagnesemia was 
statistically not significant ( p = 0 .22 ) 
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Table 14 : Retinopathy and magnesium in diabetic cases 
 
Retinopathy  
 
No. of 
cases 
Magnesium 
Hypo  
<1.3 mg /dl 
Normal Mean 
+SD 
No. % No. % 
Present  
(PDR -3 ; NPDR – 31) 
34 22 64.7 12 35.3 1.22 
+0.31 
Absent 66 17 25.8 49 74.2 1.53 
+0.36 
‘p’ 0.0001  
Significant 
 
 Percentage of hypomagnesemia cases was 64.7% in diabetic cases with 
retinopathy and 25.8% in cases without retinopathy. This relationship was 
statistically significant.( p = 0.0001)  
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Table 15 : Neuropathy and magnesium in diabetic cases 
 
Neuropathy 
 
No. of 
cases 
Magnesium 
Hypo   
<1.3 mg /dl 
Normal Mean +SD 
No. % No. % 
Present 10 5 50 5 50 1.3 +0.34 
Absent 90 34 37.8 56 62.2 1.44 +  0.37 
‘p’ 0.2641  
Not significant 
 
 Relationship between incidence of neuropathy and hypomagnesemia was 
not statistically significant. ( p = 0.2641). 
Table 16 : Nephropathy and magnesium in diabetic cases 
 
Nephropathy 
 
No. of 
cases 
Magnesium 
Hypo   
<1.3 mg /dl 
Normal Mean 
+SD 
No. % No. % 
Present 12 7 58.3 5 41.7 1.29+ 
0.38 
Absent 88 32 36.4 56 63.6 1.44 
+0.37 
‘p’ 0.2129  
Not significant 
 Among 12 patients 10 patients had  microalbuminuria 2 patients had 
macroalbuminuria There was no significant association between nephropathy 
and hypo magnesia in diabetic cases. ( p = 0.2129). 
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DISCUSSION 
Reported high prevalence of low plasma magnesium concentrations 
among diabetic subjects and possible association of hypomagnesemia with 
diabetic complications prompted this study.  
Marked magnesium deficiency has been reported in the previous studies 
in patients with type-2 diabetes.
5,7 
However, some workers have also reported 
normal and even high levels.
62 
In the present study, prevalence of serum 
magnesium concentrations in  type 2 diabetes patients was 39%. This confirms 
to the reported prevalence of low plasma magnesium status in type-2 diabetics 
in several studies, which ranged from 25 to 39%. Prevalence of 
hypomagnesemia in type – 2 diabetics in our study was similar to that reported 
by Nadler et al.
5 
in type 2 diabetics attending outpatient clinics in the US. Walti 
MK et al.
64 
also reported a prevalence of hypomagnesemia in type 2 diabetics 
at 37.6% versus 10.9% in nondiabetic controls in a study conducted in Zurich, 
Switzerland. The reasons for the high prevalence of magnesium deficiency in 
diabetes are not clear, but may include increased urinary loss, lower dietary 
intake, or impaired absorption of magnesium compared to healthy individuals. 
Several studies have reported increased urinary magnesium excretion in type 1 
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and type 2 diabetes.
7, 75 
Recently a specific tubular defect in magnesium 
reabsorption in thick ascending loop of Henle is postulated.  
This defect results in reduction in tubular reabsorption of magnesium 
and consequently hypomagnesemia. The reason for this tubular defect in 
diabetics in unclear. Insulin treatment has been shown to correct renal 
magnesium loss in diabetics. Low dietary intake is an unlikely cause of 
impaired magnesium status in diabetes. A dietary assessment conducted in 
Europe showed that only 5.4% of the diabetic group and 9.1% of the control 
group had intakes of magnesium below their individual requirements.
77 
In 
addition, recently it has been shown that type 2 diabetics in reasonable 
metabolic control absorb dietary magnesium to a similar extent as healthy 
controls. Increased urinary magnesium excretion due to hyperglycemia and 
osmotic diuresis may contribute to hypomagnesemia in diabetes. 
 Serum levels of magnesium have been found by several investigators to 
correlate inversely with fasting blood glucose concentration
62,63 
and the 
percentage of HbA1C.
62   
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 Schlienger et al.7 studied the influence of glycemic control (glycemic 
control evaluated by HbA1C) on various trace elements and reported 
significantly reduced plasma magnesium levels in patients with poor 
control of diabetes. 
The study published in the Journal of Clinical Nutrition  indicates that 
adequate levels of magnesium is closely related to normal level of blood sugar 
since the mineral has an important role in the good functioning of the insulin 
receptors found in the cells.
 74
 In this study, researchers from the University of 
Sao Paulo measured blood sugar and levels of magnesium of 51 patients who 
were being treated for type 2 diabetes. They found that 77 percent of the 
participants in the study had a deficiency of magnesium. They also found that 
there was a inverse relationship between the level of magnesium and the level 
of glucose. 
The present study revealed statistically significant (‘P’=0.0068 
&’P’=0.0013) correlation between serum magnesium levels and fasting blood 
sugar and HbA1C. Patients with poor glycemic parameters (FBS>130 mg/dl or 
HbA1c>7%) had a significantly higher prevalence of hypomagnesemia (50.8 & 
50%) compared to overall prevalence in diabetics(39%).  
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Hypomagnesemia is reported to be both a cause and result of poor 
glycemic control. Magnesium is a cofactor in both glucose transporting 
mechanisms of cell membrane and various enzymes important in carbohydrate 
oxidation.
4 
In addition, magnesium deficiency has been shown to promote 
insulin resistance in multiple studies. Nadler et al.
8 
have reported that insulin 
sensitivity decreases even in nondiabetic individuals after induction of 
magnesium deficiency. Like wise, elderly subjects were shown to have 
improved glucose tolerance when they received magnesium supplements. Thus 
hypomagnesemia by itself results in poor glycemic control. Conversely, 
hyperglycemia and osmotic diuresis may lead to increased urinary magnesium 
excretion and hypomagnesemia in diabetics. However, high prevalence of 
hypomagnesemia have also been reported  in  type – 2 diabetics with good 
glycemic control.
5 
 
Sex, age and duration of diabetes were not the significant predictors of 
serum magnesium levels. Yajnick et al.
62 
in 1984 reported that among diabetics 
plasma magnesium concentration was directly related to age and men had 
significantly higher concentrations than women. The increasing magnesium 
levels with age were probably due to impaired renal function and the sample 
size, (87 diabetics, 30 non diabetics) was relatively small to confirm male 
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preponderance. In our study, patients with impaired renal functions were 
excluded. Our results confirm to the recent reports that have not shown any 
significant associations between sex and age but duration of diabetes inversly 
correlates with serum magnesium levels. Duration of diabetic was 
7.79+2.13meanyears in hypomagnesemia group where as 6.25+1.6 years  in 
cases with normal magnesium.      
Yajnik et al.
62 
reported that insulin treated diabetics have significantly 
lower serum magnesium levels compared to non insulin treated ones. In that  
study prevalence of hypomagnesemia in insulin treated diabetics was higher 
than in noninsulin treated (32.2% v/s 30.4%). However, the difference was 
statistically not significant. Walti MK et al
77 
have reported that diabetes 
treatment (insulin or OHA) did not significantly predict hypomagnesemia. 
Redistribution of magnesium from plasma in to red blood cells is caused by 
insulin. In a recent study Alzaida et al.
63 
have found that cellular uptake of 
magnesium is normally stimulated by insulin. So insulin treatment may 
enhance cellular magnesium uptake and result in increased prevalence of 
hypomagnesemia.In present study there was no patient treated with Insulin 
alone and so the significance could not be determined. 
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In the present study, no correlation was found between incidence of 
ischemic heart disease and hypomagnesemia. However, several observational 
studies have associated lower serum levels of serum magnesium with higher 
risk of coronary artery disease. As part of Atherosclerosis risk in communities 
study, a cohort of 15,792 subjects were studied over 7 years and an increasing 
relative risk of coronary artery disease with decreasing serum magnesium was 
reported.
80
 How a low serum magnesium predisposes to coronary artery 
diseases is not known. However, in the present study, no difference in 
prevalence of hypomagnesemia was found between those with ischemic heart 
disease and others. Similarly, no difference in prevalence of hypomagnesemia 
was found between the hypertensive and non hypertensive subjects. 
Previously magnesium deficiency has been found to be associated with diabetic 
microvascular disease. In the present study too significantly higher prevalence 
of hypomagnesemia was observed in diabetics with microvascular 
complications and mean serum concentration of magnesium in diabetics with 
microvascular complications was comparatively lower than in diabetics with 
no microvascular complications. 
Hypomagnesemia has been reported in patients with diabetic 
retinopathy, with lower magnesium levels predicting a greater risk of severe 
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diabetic retinopathy.
10 
Our observations revealed a definite association between 
diabetic retinopathy and lower serum magnesium levels. There was a 
significant difference in prevalence of hypomagnesemia in diabetics with 
retinopathy and without retinopathy (64.5% vs 25.8%; P< 0.0001). These 
observations are similar to other reports. The mechanism by which 
hypomagnesemia predisposes to diabetic retinopathy is not clear. Grafton et 
al.
4 
have proposed the inositol transport theory to explain this association. But 
the exact reason remains obscure.   
With reference to other diabetic microangiopathies, no significant 
association was found between prevalence of hypomagnesemia, diabetic 
neuropathy and diabetic nephropathy. . The patients with diabetic 
nephropathy(58.3%) had a slightly higher prevalence of hypomagnesemia 
compared to those with neuropathy(50%).But the difference was statistically 
insignificant. Even within the nephropathy group, no difference was found 
between patients with microalbuminuria and macroalbuminuria. These results 
are similar to those reported by Pickup et al.
77 
who found no difference in 
serum magnesium concentrations between diabetics with microalbuminuria or 
clinical proteinuria compared to diabetics with normal albumin excretion. 
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In contrast, Corsonello, et al demonstrated significantly lower serum 
magnesium in type 2 diabetics with nephropathy compared to a 
normoalbuminemic group. They argued that in diabetics with nephropathy, 
serum magnesium might be reduced because of lower serum albumin 
concentration, as 30% of serum magnesium is bound to proteins, mainly 
albumin. 
In summary, the present study has demonstrated that hypomagnesemia is 
common in type 2 diabetics and magnesium deficiency is conclusively 
associated with diabetic retinopathy. So it may be prudent to consider 
Magnesium Deficiency as a contributing factor in many Diabetic 
Complications and in the Exacerbation of the disease itself. 
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CONCLUSION 
1. Prevalence of hypomagnesemia in type 2 diabetes is 39%.  
2. Hypomagnesemia has significant association with glycemic control 
which was reflected in uncontrolled fasting blood sugar (FBS >130 
mg%) and Hb A1C >7 (p value 0.0068) & (p value0.0013 ) respectively.   
3. Hypomagnesemia have no significant relation with age, sex and 
treatment mode of the diabetic patients  but it has significant association 
with duration of diabetes.   
4. Hypomagnesemia is significantly associated with diabetic retinopathy  
(p value 0.0001).  
5. No significant association between other diabetic microangiopathies 
(nephropathy and neuropathy) and diabetic comorbidities – ischemic 
heart disease and hypertension.  
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LIMITATION OF STUDY 
 Study can be extended to large population.  
 Study can be carried out in Type 1 diabetic patients .  
 Correlation of Hypomagnesemia & dyslipedemia in  diabetes  can be 
studied because dyslipedemia is commonly associated diabetes.   
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PROFORMA  
Serial No. :  
Patient Details  
Name :  
Hospital No. :  
Age /Sex :  
Occupation :  
Diabetic History  
Age of onset :  
Total Duration :  
Mode of Treatment : OHA/I/OHA+I 
Symptoms Related to Complications  
A) Symptoms of Neuropathy  
• Postural dizziness  
• Numbness/parasthesia /weakness/Pain/hyperaesthesia   
• Bladder incontinence/Impotence   
B) Symptoms of Nephropathy - Oliguria /Oedema   
C) Symptoms of Retinopathy  - Dimness of vision /Blindness  
Past History : IHD/ HTN   
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Family History: DM / IHD/ HTN  
Examination  
Height : Weight :  
General Examination:  
Pulse Rate: Icterus : Cyanosis: Clubbing: Lymph Nodes: Edema:  
BP: Supine: Standing:  
A. Sensory motor Neuropathy  
• Loss of pain and temperature/touch /position and vibration sense   
• Rhomberg test  
B. Proximal Muscle Neuropathy  
• Wasting /Power/Tone   
• Knee jerk /Ankle jerk   
C. Eye Signs  
• Diabetic retionopathy : Non Proliferative / Proliferative   
D. Signs of nephropathy - Oedema / Facial puffiness   
Investigations  
1. FBS: HbA1C :                       5. Routine Urine:Sugar:/Protein/Microscopy:      
2. Serum Magnesium:               6. ECG/ Echocardiogram:  
3. 24 hour albuminiuria:           7.Direct opthalmoscopy :  
4. Serum: Creatinine:  
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LIST OF ABBREVIATIONS  
DM   -  Diabetes Mellitus  
FBS   -  Fasting Blood Sugar  
GDM   -  Gestational Diabetes Mellitus  
HbA1C  -  Glycosylated Haemoglobin  
HTN    -  Hypertension  
IFG    -  Impaired Fasting Glucose  
IGT    -  Impaired Glucose Tolerance  
NIDDM   -  Non-Insulin Dependent Diabetes Mellitus  
OGTT  -  Oral Glucose Tolerance Test  
UKPDS  -  United Kingdom Prospective Diabetes Study 
IHD   -   Ischemic Heart Disease 
TRPM6 - Transient Receptor Potential channel Melastatin 6 
HTN  - Hypertension  
PDR  - Proliferative diabetic retinopathy  
NPDR  - Non proliferative diabetic retinopathy 
SrMg  - Serum maganesium   
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MASTER CHART 
No   AGE  sex  DURATION  TREATMENT  IHD  HTN  RETINOPATHY  NEUROPATHY  NEPHROPATHY  FBS in mg %  HbA1c  Sr.Mg. in mg 
1  60  M  10  OHA + I  ‐  ‐‐‐  NPDR  ‐  ‐  140 8.5 1 
2  55  F  7  OHA  ‐  ‐  ‐  ‐  ‐  135 7.2 1 
3  59  M  8  OHA  ‐  ‐  NPDR  ‐  ‐  138 7.6 1.4 
4  46  M  4  OHA  ‐  ‐  ‐  ‐  ‐  110 6.8 1.5 
5  50  F  7  OHA  ‐  ‐  NPDR  ‐  ‐  150 8.6 0.9 
6  66  F  8  OHA+ I  ‐  ‐  NPDR  +  MICROALBUM+  130 7 1.5 
7  55  F  5  OHA  ‐  ‐  ‐  ‐  ‐  130 7 1.2 
8  58  M  7  OHA  ‐  +  ‐  ‐  ‐  135 7.6 1.6 
9  57  M  6  OHA  ‐  +  ‐  ‐  ‐  130 7.5 1.5 
10  70  M  10  OHA  ‐  ‐  PDR  ‐  ‐  155 9 1.2 
11  50  F  4  OHA  ‐  ‐  ‐  ‐  ‐  138 7.2 1.6 
12  43  F  3  OHA  ‐  ‐  ‐  ‐  ‐  100 6.5 2 
13  60  M  7  OHA + I  ‐  ‐  NPDR  ‐  ‐  135 7 1.5 
14  54  M  6  OHA  ‐  ‐  ‐  ‐  ‐  145 8 0.9 
15  58  F  7  OHA  ‐  +  ‐  ‐  ‐  110 6.5 1.5 
16  48  F  4  OHA  ‐  ‐  ‐  ‐  ‐  128 7 2.2 
17  65  M  10  OHA  ‐  ‐  NPDR  +  MICROALBUM+  145 8 1 
18  66  M  10  OHA  +  ‐  ‐  ‐  ‐  117 6.8 1.5 
19  55  F  7  OHA  ‐  ‐  ‐  ‐  ‐  148 8 1 
20  59  M  8  OHA + I  ‐  ‐  NPDR  ‐  ‐  150 8 0.9 
21  60  M  7  OHA  ‐  ‐  NPDR  ‐  ‐  143 7.5 1 
22  48  F  4  OHA  ‐  ‐  ‐  ‐  ‐  142 7.8 1.7 
23  52  M  6  OHA  ‐  ‐  ‐  ‐  ‐  146 8 1.2 
24  54  F  6  OHA  ‐  ‐  ‐  ‐  ‐  150 8.5 1.6 
25  57  F  7  OHA  ‐  ‐  NPDR  ‐  ‐  140 8 1 
26  55  M  6  OHA  ‐  ‐  ‐  ‐  ‐  135 7.5 1.5 
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27  65  M  8  OHA  +  ‐  ‐  ‐  ‐  126 7 1.5 
28  67  M  9  OHA  ‐  +  ‐  ‐  ‐  140 7.3 1.2 
29  56  F  7  OHA + I  ‐  ‐  ‐  +  ‐  133 7 1.7 
30  60  F  8  OHA  ‐  ‐  NPDR  +  ‐  138 7.4 1 
31  66  F  12  OHA  ‐  ‐  NPDR  ‐  ‐  148 8.2 1 
32  63  M  10  OHA  ‐  ‐  NPDR  ‐  ‐  145 8 1.5 
33  58  M  8  OHA  ‐  +  ‐  ‐  ‐  124 7 2.2 
34  55  M  7  OHA  ‐  +  ‐  ‐  MICROALBUM+  110 6.8 1.8 
35  70  F  15  OHA  ‐  ‐  PDR  +  MICROALBUM+  150 8.6 0.9 
36  53  F  5  OHA  ‐  ‐  ‐  ‐  ‐  110 7 1.7 
37  60  M  7  OHA  ‐  +  ‐  +  ‐  140 7.8 1.5 
38  54  M  5  OHA  ‐  +  ‐  ‐  ‐  136 7.2 2 
39  60  M  6  OHA  +  +  ‐  ‐  ‐  128 7 0.6 
40  58  M  7  OHA  +  +  ‐  ‐  ‐  124 7 1.2 
41  50  F  4  OHA  ‐  ‐  ‐  ‐  ‐  100 7 2 
42  56  F  5  OHA  ‐  ‐  ‐  ‐  ‐  105 7 1.9 
43  60  M  10  OHA + I  ‐  ‐  NPDR  ‐  ‐  128 7.2 1.6 
44  58  M  7  OHA  ‐  ‐  ‐  ‐  ‐  140 7.5 1.8 
45  50  M  6  OHA  ‐  ‐  ‐  ‐  ‐  110 7 1.5 
46  66  M  10  OHA  ‐  ‐  NPDR  ‐  ‐  138 7.4 1 
47  55  M  5  OHA  ‐  ‐  NPDR  ‐  ‐  132 7 1.7 
48  58  F  7  OHA  ‐  +  ‐  ‐  ‐  133 7 1.5 
49  55  F  6  OHA  ‐  ‐  ‐  ‐  ‐  150 8.4 0.9 
50  52  M  5  OHA  ‐  ‐  ‐  ‐  ‐  136 7.2 1.5 
51  55  M  7  OHA + I  ‐  +  ‐  ‐  ‐  124 7 1.7 
52  65  M  9   OHA + I  ‐  +  ‐  ‐  ‐  143 8 1 
53  57  M  6  OHA  +  +  ‐  ‐  ‐  123 7 1.5 
54  60  F  8  OHA  ‐  ‐  NPDR  ‐  ‐  130 7.2 1.6 
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55  54  F  5  OHA  ‐  ‐  ‐  ‐  ‐  136 7.5 1.4 
56  58  M  7  OHA  ‐  +  ‐  ‐  ‐  145 8 1.5 
57  48  F  4  OHA  ‐  ‐  ‐  ‐  ‐  130 7.2 1.6 
58  62  M  7  OHA  ‐  ‐  NPDR  ‐  ‐  128 7.5 1.8 
59  57  M  7   OHA + I  ‐  ‐  NPDR  ‐  ‐  140 7.5 1 
60  55  F  7  OHA  ‐  +  ‐  ‐  ‐  113 6.8 1.2 
61  50  F  4  OHA  ‐  ‐  ‐  ‐  ‐  155 8.3 1.7 
62  43  F  3  OHA  ‐  ‐  ‐  ‐  ‐  145 8 1.5 
63  58  F  7  OHA  +  +  ‐  ‐  ‐  118 7 1.5 
64  60  M  8  OHA  ‐  ‐  NPDR  ‐  ‐  130 7.2 0.9 
65  56  F  5  OHA  ‐  ‐  ‐  ‐  ‐  110 7.5 2.2 
66  55  M  6  OHA  ‐  +  ‐  ‐  ‐  110 7.3 1 
67  65  F  8  OHA  ‐  ‐  NPDR  ‐  ‐  128 7.5 1.2 
68  70  M  10  OHA  ‐  ‐  PDR  ‐  ‐  135 7.8 1 
69  58  M  7  OHA  ‐  ‐  ‐  ‐  ‐  140 8 1 
70  56  M  7  OHA  ‐  ‐  ‐  ‐  ‐  136 7.2 1.2 
71  50  M  5  OHA  ‐  ‐  ‐  ‐  ‐  110 6.8 1.5 
72  56  F  6  OHA  ‐  ‐  NPDR  +  MICROALBUM+  135 7.2 1.9 
73  45  F  5  OHA  ‐  ‐  ‐  ‐  ‐  100 7 1.7 
74  54  M  6  OHA  ‐  ‐  ‐  ‐  ‐  100 6.5 2 
75  65  F  8  OHA  ‐  ‐  NPDR  ‐  MACROALBUM+  130 7.2 1.1 
76  48  F  4  OHA  ‐  ‐  ‐  ‐  ‐  128 6.8 2.2 
77  55  M  10  OHA  +  ‐  NPDR  +  ‐  145 8 1 
78  58  M  7  OHA  ‐  ‐  ‐  ‐  ‐  145 8 2 
79  59  M  8  OHA  ‐  ‐  NPDR  ‐  MACROALBUM+  126 7 1.5 
80  55  M  7  OHA  ‐  ‐  ‐  ‐  ‐  148 8 1.5 
81  60  M  8  OHA  ‐  ‐  ‐  ‐  ‐  136 8.2 1.7 
82  65  M  8  OHA  ‐  +  NPDR  ‐  MICROALBUM+  140 8.3 1 
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83  56  M  6  OHA  ‐  ‐  ‐  ‐  ‐  140 7.5 1.4 
84  59  M  8  OHA  ‐  ‐  ‐  ‐  ‐  145 7.9 1.6 
85  57  M  5  OHA  ‐  ‐  ‐  ‐  ‐  130 7.2 1.8 
86  60  F  7  OHA  ‐  ‐  ‐  ‐  ‐  130 7.2 1.7 
87  48  F  4  OHA  ‐  ‐  ‐  ‐  ‐  140 7.8 1.2 
88  65  M  8  OHA  ‐  +  NPDR  ‐  MICROALBUM+  145 8 1.2 
89  58  M  8  OHA  ‐  ‐  NPDR  +  ‐  130 7 1.5 
90  55  F  6  OHA  ‐  ‐  ‐  ‐  ‐  145 7.9 1 
91  60  M  7  OHA  ‐  ‐  ‐  ‐  ‐  145 8 1.5 
92  60  M  7  OHA  ‐  ‐  ‐  ‐  ‐  150 8 1.5 
93  65  M  8  OHA  ‐  ‐  ‐  ‐  ‐  135 7.5 1.7 
94  55  M  5  OHA  ‐  ‐  ‐  ‐  ‐  110 7.5 2.2 
95  60  M  10  OHA  +  ‐  NPDR  +  MICROALBUM+  145 8 1 
96  48  F  4  OHA  ‐  ‐  ‐  ‐  ‐  155 8.3 1.7 
97  54  M  8  OHA + I  ‐  ‐  NPDR  ‐  ‐  130 7.5 1 
98  60  M  8  OHA  ‐  ‐  NPDR  ‐  MICROALBUM+  136 7.5 0.9 
99  55  F  6  OHA  ‐  ‐  NPDR  ‐  MICROALBUM+  148 7.8 1.2 
100  54  M  5  OHA  ‐  ‐  ‐  ‐  ‐  130 7.2 1.5 
                       
CONTROL GROUP 
No   AGE  SEX  FBS  HbA1c  Sr.Mg.  HTN  IHD  RETINOPATHY  NEUROPATHY  NEPHROPATHY     
1  54  M  107  6.2  1.7  ‐  ‐  ‐  ‐  ‐     
2  45  M  96  6.5  2.2  ‐  ‐  ‐  ‐  ‐     
3  48  F  105  6.3  1.8  ‐  ‐  ‐  ‐  ‐     
4  60  M  98  6.9  2  ‐  ‐  ‐  ‐  ‐     
5  48  M  100  5.9  1.9  ‐  ‐  ‐  ‐  ‐     
6  46  F  100  6.7  1.5  ‐  ‐  ‐  ‐  ‐     
7  61  F  102  6.1  2.1  ‐  ‐  ‐  ‐  ‐     
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8  55  M  102  5.5  2.4  ‐  ‐  ‐  ‐  ‐     
9  58  M  110  6  1.9  ‐  ‐  ‐  ‐  ‐     
10  49  M  98  5.8  1.7  ‐  ‐  ‐  ‐  ‐     
11  43  F  102  5.3  2.2  ‐  ‐  ‐  ‐  ‐     
12  59  M  101  6.2  2  ‐  ‐  ‐  ‐  ‐     
13  60  M  106  6.3  1.8  ‐  ‐  ‐  ‐  ‐     
14  67  F  100  7  1.3  ‐  ‐  ‐  ‐  ‐     
15  53  M  98  6.7  2.3  ‐  ‐  ‐  ‐  ‐     
16  64  M  97  6.6  2.1  ‐  ‐  ‐  ‐  ‐     
17  57  F  103  5.7  1.9  ‐  ‐  ‐  ‐  ‐     
18  56  M  108  6  1.8  ‐  ‐  ‐  ‐  ‐     
19  61  F  101  6.2  2.2  ‐  ‐  ‐  ‐  ‐     
20  53  M  98  6.3  2  ‐  ‐  ‐  ‐  ‐     
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